Tomoki Inagaki

(稲垣知希)

Profile Information

Design, development, and evaluation of gene therapeutics specific to KSHV-associated diseases

Tomoki Inagaki, Jonna Magdallene Espera, Kang-Hsin Wang, Somayeh Komaki, Sonali Nair, Ryan R. Davis, Ashish Kumar, Ken-ichi Nakajima, Yoshihiro Izumiya

Molecular Therapy Oncology, Sep, 2025
Studies on Gene Enhancer with KSHV mini-chromatin

Tomoki Inagaki, Ashish Kumar, Kang-Hsin Wang, Somayeh Komaki, Jonna M. Espera, Christopher S. A. Bautista, Ken-ichi Nakajima, Chie Izumiya, Yoshihiro Izumiya

Mar 24, 2025
The Role of vIL-6 in KSHV-Mediated Immune Evasion and Tumorigenesis

Somayeh Komaki, Tomoki Inagaki, Ashish Kumar, Yoshihiro Izumiya

Viruses, Dec 10, 2024
A LANA peptide inhibits tumor growth by inducing CHD4 protein cleavage and triggers cell death

Hiroki Miura, Kang-Hsin Wang, Tomoki Inagaki, Frank Chuang, Michiko Shimoda, Chie Izumiya, Tadashi Watanabe, Ryan R. Davis, Clifford G. Tepper, Somayeh Komaki, Ken-ichi Nakajima, Ashish Kumar, Yoshihiro Izumiya

Cell Chemical Biology, Nov, 2024
An atlas of chromatin landscape in KSHV-infected cells during de novo infection and reactivation

Tomoki Inagaki, Ashish Kumar, Somayeh Komaki, Ken-Ichi Nakajima, Yoshihiro Izumiya

Virology, Sep, 2024